Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A., a foreign private issuer, covers the month of December 2022. The report, dated December 19, 2022, incorporates by reference a press release (Exhibit 99.1) and is signed by Mondher Mahjoubi, Chairman of the Executive Board and CEO.
Key Financial Metrics
The filing text provided does not contain specific financial data. No values for revenue, profit, cash flow, margins, debt, or liquidity are disclosed in this document.
Material Changes
The filing text does not provide information regarding material changes versus prior comparable periods.
Guidance, Outlook, and Risks
The filing text does not include management commentary, guidance, outlook, risks, contingencies, or details on unusual items. The document serves primarily as a cover sheet incorporating an external press release.
Investor Verification Checklist
- Review the full text of the press release dated December 19, 2022 (Exhibit 99.1) for the specific announcement details.
- Verify the impact of the announcement on the company's pipeline or strategic direction.
- Check subsequent filings for any financial updates related to the event disclosed in the press release.